Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/suppressive phenotype

Haematologica

Volumn 90, Issue 4, 2005, Pages 516-525

  Maccario, Rita ^a   Podestà, Marina ^b   Moretta, Antonia ^a   Cometa, Angela ^a   Comoli, Patrizia ^a   Montagna, Daniela ^a   Daudt, Liane ^a   Ibatici, Adalberto ^b   Piaggio, Giovanna ^b   Pozzi, Sarah ^b   Frassoni, Francesco ^b   Locatelli, Franco ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Ospedale San Carlo   (Italy)

Author keywords

Dendritic cells (DC); Mesenchymal stem cells (MSC); Mixed lymphocyte culture (MLC); Regulatory T cells; Tolerance

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANTIGEN SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; MESENCHYME CELL; MIXED LYMPHOCYTE CULTURE; NATURAL KILLER CELL; ORGAN TRANSPLANTATION; RECIPIENT; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; EPITOPES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; ISOANTIGENS; LYMPHOCYTE CULTURE TEST, MIXED; MESENCHYMAL STEM CELLS; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 17844391825     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
2. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000;28:875-84.
3. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
4. Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 2002;30:870-8.
5. in't Anker PS, Noort WA, Kruisselbrink AB, Scherion SA, Beekhuizen W, Willemze R, et al. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 2003;31:881-9.
6. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemiotherapy. J Clin Oncol 2000;18:307-20.
7. Koc ON, Lazarus HM. Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant 2001;27:235-9.
8. Fibbe WE, Noort WA. Mesenchymal stem cells and hematopoietic stem cell transplantation. Ann NY Acad Sci 2003;996:235-44.
9. Frassoni F, Labopen M, Bacigalupo A. Expanded mesenchymal stem cells (MSC), co-infused with HLA-identical hematopoietic stem cell transplant, reduce acute and chronic graft versus host disease: a matched pair analysis [abstract]. Bone Marrow Transplant 2002;29 Suppl 2:75.
10. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
11. McIntosh K, Bartholomew A. Stromal cell modulation of the immune system: a potential Role for mesenchymal stem cells. Graft 2000;3:324-8.
12. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and pro-long skin graft survival in vivo. Exp Hematol 2002;30:42-8.
13. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non specific mitogeni stimuli. Blood 2002;99:3838-43.
14. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implication in transplantation. Transplantation 2003;75:389-97.
15. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
16. Le Blanc K, Tammik L, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-6.
17. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
18. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-44.
19. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21.
20. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutmin-activated lymphocytes. Scand J Immunol. 2004;60:307-15.
21. Aggarwal S, Pittinger MF. Human mesenchymal stem cells modulate alloantigen immune cell responses. Blood 2005;105:1815-22.
22. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 2005;1501:2214-9.
23. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood [Epub ahead of print]
24. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-01.
25. Moretta A, Maccario R, Fagioli F, Giraldi E, Busca A, Montagna D, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001;29:371-9
26. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-90.
27. Comoli P, Montagna D, Moretta A, Zecca M, Locatelli F, Maccario R. Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro. J Immunol 1995;155:5506-11.
28. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin invest 1995;95:341-9.
29. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
30. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001;193:F5-9.
31. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nature Rev Immunol 2003;3:253-7.
32. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
33. Montagna D, Maccario R, Ugazio AG, Nespoli L, Fedroni E, Faggiano P, et al. Cell-mediated cytotoxicity in Down-syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities. Eur J Pediatr 1988;148:53-7.
34. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
35. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
36. Strobl H, Knapp W. TGF-1 regulation of dendritic cells. Microbes Infect 1999;1:1283-91.
37. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004;172:4676-80.
38. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994;179:1109-18.
39. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-22.
40. +CD25-cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 2004;172:5213-21.
41. + regulatory cells and infectious tolerance. Transplantation 2004;77:S23-5.
42. +) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94.
43. + T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-10.
44. + T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004;104:453-61.
45. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nature Rev Immunol 2003;3:199-210.
46. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003;112:1688-96.
47. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 2004;103:1140-6.
48. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004;103:2410-6.
49. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995;92:811-5.